[Experience with ceftazidime in the field of obstetrics and gynecology].
Ceftazidime ( CAZ ), a new cephalosporin antibiotic, was studied for transference into tissues and clinical efficacy in the field of obstetrics and gynecology, and the following results were obtained: After one shot intravenous injection of CAZ 1 g, favourable transference of CAZ into uterine tissues was observed. While the mean serum level at 1 hour after the administration was 50.2 micrograms/ml, the levels in oviduct, ovary, endometrium, myometrium, cervix uteri and portio vaginalis were 25.9, 31.6, 24.9, 24.5, 34.2 micrograms/g and 40.6 micrograms/g, respectively. The half-life of CAZ in these tissues ranged from 1.16 to 1.65 hours while that in serum was 1.24 hours. The peak level in retroperitoneal space exudate (25.3 micrograms/ml) was obtained at 3 hours after one shot intravenous injection of CAZ 1 g. The level was still as high as 2.68 micrograms/ml even 12 hours after the administration. Out of 4 cases of obstetric and gynecological infections, 3 cases were assessable, CAZ was effective in these 3 assessable cases. Neither adverse effects nor abnormalities in laboratory findings due to CAZ were observed. Based on these results, CAZ is considered to be an highly effective antibiotic with good transference into uterine tissues and clinical efficacy in obstetric and gynecological infections.
D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy*; D002442:Ceftazidime; D002511:Cephalosporins / Q000009:adverse effects / Q000378:metabolism* / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy*; D006207:Half-Life; D006801:Humans; D008875:Middle Aged; D011247:Pregnancy; D011645:Puerperal Infection / Q000188:drug therapy; D012187:Retroperitoneal Space / Q000378:metabolism; D014599:Uterus / Q000378:metabolism
D002511:Cephalosporins; D002442:Ceftazidime